Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Código QR

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Avgerinos I, Liakos A, Tsapas A, Bekiari E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dapagliflozin sodium-glucose co-transporter 2 (sglt-2) inhibitors type 2 diabetes cardiovascular risk Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men P, et al.
Publicado: (2020)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer MF, et al.
Publicado: (2016)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
por: Contreras,Álvaro, et al.
Publicado: (2019)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis
por: Huang H, et al.
Publicado: (2018)

Vascular Age as a Cardiovascular Risk Marker in Asymptomatic Patients with Type 2 Diabetes
por: Palma CCSSV, et al.
Publicado: (2020)

Attainment of recommended therapeutic targets of modifiable cardiovascular risk factors among individuals with type 2 diabetes mellitus screened at a diabetes clinic in Sri Lanka
por: Weerarathna TP, et al.
Publicado: (2018)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
por: Hirai K, et al.
Publicado: (2020)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
por: Angelo Avogaro
Publicado: (2018)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
por: Kwong-Man Ng, et al.
Publicado: (2018)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch J
Publicado: (2010)

Statin on insulin and adiponectin levels: true or false prophecy?
por: Jonnalagadda VG, et al.
Publicado: (2018)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
por: Sergey V. Kakorin, et al.
Publicado: (2016)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Muhammad Afzal, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Aurélie Pahud de Mortanges, et al.
Publicado: (2021)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
por: Hinnen D, et al.
Publicado: (2019)

The Factors Influencing the Renal Glucose Threshold in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Cui SS, et al.
Publicado: (2021)